{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:35:34Z","timestamp":1776288934609,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:00:00Z","timestamp":1426723200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12943-015-0329-x","type":"journal-article","created":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:57:42Z","timestamp":1426640262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["TNF\u03b1 sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-\u03baB-mediated expression of Fas"],"prefix":"10.1186","volume":"14","author":[{"given":"Koen MO","family":"Galenkamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Carriba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Urresti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Planells-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Lopez-Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Barneda-Zahonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana S","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel F","family":"Segura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan X","family":"Comella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,19]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"G Brodeur","year":"2003","unstructured":"Brodeur G. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203\u201316.","journal-title":"Nat Rev Cancer"},{"key":"329_CR2","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"J Maris","year":"2010","unstructured":"Maris J. Medical progress: recent advances in neuroblastoma. N Engl J Med. 2010;362:2202\u201311.","journal-title":"N Engl J Med"},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"J Maris","year":"2007","unstructured":"Maris J, Hogarty M, Bagatell R, Cohn S. Neuroblastoma. Lancet. 2007;369:2106\u201320.","journal-title":"Lancet"},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","volume":"12","author":"WP Roos","year":"2006","unstructured":"Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440\u201350.","journal-title":"Trends Mol Med"},{"key":"329_CR5","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.cellsig.2012.02.006","volume":"24","author":"L Cabal-Hierro","year":"2012","unstructured":"Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012;24:1297\u2013305.","journal-title":"Cell Signal"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1096\/fj.08-111005","volume":"23","author":"ME Guicciardi","year":"2009","unstructured":"Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23:1625\u201337.","journal-title":"FASEB J"},{"key":"329_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1310050","volume":"370","author":"A Linkermann","year":"2014","unstructured":"Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370:455\u201365.","journal-title":"N Engl J Med"},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/bph.12238","volume":"169","author":"O Micheau","year":"2013","unstructured":"Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol. 2013;169:1723\u201344.","journal-title":"Br J Pharmacol"},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.bcp.2010.03.011","volume":"80","author":"M Russo","year":"2010","unstructured":"Russo M, Mupo A, Spagnuolo C, Russo GL. Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol. 2010;80:674\u201382.","journal-title":"Biochem Pharmacol"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.molmed.2013.03.002","volume":"19","author":"A Martin-Villalba","year":"2013","unstructured":"Martin-Villalba A, Llorens-Bobadilla E, Wollny D. CD95 in cancer: tool or target? Trends Mol Med. 2013;19:329\u201335.","journal-title":"Trends Mol Med"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/mc.20700","volume":"50","author":"E Grau","year":"2011","unstructured":"Grau E, Martinez F, Orellana C, Canete A, Yanez Y, Oltra S, et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog. 2011;50:153\u201362.","journal-title":"Mol Carcinog"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/75007","volume":"6","author":"T Teitz","year":"2000","unstructured":"Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6:529\u201335.","journal-title":"Nat Med"},{"key":"329_CR13","first-page":"5897","volume":"62","author":"K Harada","year":"2002","unstructured":"Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62:5897\u2013901.","journal-title":"Cancer Res"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s001090100233","volume":"79","author":"T Teitz","year":"2001","unstructured":"Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med. 2001;79:428\u201336.","journal-title":"J Mol Med"},{"key":"329_CR15","doi-asserted-by":"crossref","unstructured":"Rauert H, Stuehmer T, Bargou R, Wajant H, Siegmund D. TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis. 2011;2:e194.","DOI":"10.1038\/cddis.2011.78"},{"key":"329_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1600-0609.1999.tb01138.x","volume":"63","author":"M Borset","year":"1999","unstructured":"Borset M, Hjorth-Hansen H, Johnsen AC, Seidel C, Waage A, Espevik T, et al. Apoptosis, proliferation and NF-kappa B activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor. Eur J Haematol. 1999;63:345\u201353.","journal-title":"Eur J Haematol"},{"key":"329_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0022-2143(99)90201-9","volume":"134","author":"M Tsuboi","year":"1999","unstructured":"Tsuboi M, Kawakami A, Nakashima T, Matsuoka N, Urayama S, Kawabe Y, et al. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med. 1999;134:222\u201331.","journal-title":"J Lab Clin Med"},{"key":"329_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","volume":"83","author":"M Grell","year":"1995","unstructured":"Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor-necrosis-factor is the prime activating ligand of the 80 KDA tumor-necrosis-factor receptor. Cell. 1995;83:793\u2013802.","journal-title":"Cell"},{"key":"329_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1073\/pnas.95.2.570","volume":"95","author":"M Grell","year":"1998","unstructured":"Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998;95:570\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"329_CR20","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1128\/MCB.23.4.1428-1440.2003","volume":"23","author":"N Holler","year":"2003","unstructured":"Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428\u201340.","journal-title":"Mol Cell Biol"},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fimmu.2013.00139","volume":"4","author":"T So","year":"2013","unstructured":"So T, Croft M. Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules. Front Immunol. 2013;4:139.","journal-title":"Front Immunol"},{"key":"329_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/cddis.2013.25","volume":"4","author":"F Marques-Fernandez","year":"2013","unstructured":"Marques-Fernandez F, Planells-Ferrer L, Gozzelino R, Galenkamp KMO, Reix S, Llecha-Cano N, et al. TNF alpha induces survival through the FLIP-L-dependent activation of the MAPK\/ERK pathway. Cell Death Dis. 2013;4:12.","journal-title":"Cell Death Dis"},{"key":"329_CR23","first-page":"2425","volume":"12","author":"MS Rodriguez","year":"1996","unstructured":"Rodriguez MS, Wright J, Thompson J, Thomas D, Baleux F, Virelizier JL, et al. Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene. 1996;12:2425\u201335.","journal-title":"Oncogene"},{"key":"329_CR24","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","volume":"20","author":"SD Catz","year":"2001","unstructured":"Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20:7342\u201351.","journal-title":"Oncogene"},{"key":"329_CR25","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1128\/MCB.21.16.5299-5305.2001","volume":"21","author":"O Micheau","year":"2001","unstructured":"Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappa B signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21:5299\u2013305.","journal-title":"Mol Cell Biol"},{"key":"329_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/hep.510290102","volume":"29","author":"S Jian","year":"1999","unstructured":"Jian S, Song MJ, Shin EC, Lee MO, Kim SJ, Park JH. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology. 1999;29:101\u201310.","journal-title":"Hepatology"},{"key":"329_CR27","first-page":"3823","volume":"57","author":"S Fulda","year":"1997","unstructured":"Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1\/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823\u20139.","journal-title":"Cancer Res"},{"key":"329_CR28","doi-asserted-by":"publisher","first-page":"10057","DOI":"10.1073\/pnas.94.19.10057","volume":"94","author":"ZL Chu","year":"1997","unstructured":"Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control. Proc Natl Acad Sci U S A. 1997;94:10057\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"329_CR29","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/sj.onc.1205255","volume":"21","author":"S Fulda","year":"2002","unstructured":"Fulda S, Debatin KM. IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene. 2002;21:2295\u2013308.","journal-title":"Oncogene"},{"key":"329_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.onc.1200201","volume":"17","author":"W Lutz","year":"1998","unstructured":"Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFN gamma cooperate in apoptosis of human neuroblastoma cells. Oncogene. 1998;17:339\u201346.","journal-title":"Oncogene"},{"key":"329_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/sj.cdd.4400537","volume":"6","author":"F Bernassola","year":"1999","unstructured":"Bernassola F, Scheuerpflug C, Herr I, Krammer PH, Debatin KM, Melino G. Induction of apoptosis by IFN gamma in human neuroblastoma cell lines through the CD95\/CD95L autocrine circuit. Cell Death Differ. 1999;6:652\u201360.","journal-title":"Cell Death Differ"},{"key":"329_CR32","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/MCB.19.3.2098","volume":"19","author":"H Chan","year":"1999","unstructured":"Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human fas promoter requires NF-kappa B p50-p65 recruitment. Mol Cell Biol. 1999;19:2098\u2013108.","journal-title":"Mol Cell Biol"},{"key":"329_CR33","doi-asserted-by":"publisher","first-page":"25530","DOI":"10.1074\/jbc.M112.356279","volume":"287","author":"FY Liu","year":"2012","unstructured":"Liu FY, Bardhan K, Yang DF, Thangaraju M, Ganapathy V, Waller JL, et al. NF-kappa B Directly regulates Fas Transcription to modulate Fas-mediated Apoptosis and tumor suppression. J Biol Chem. 2012;287:25530\u201340.","journal-title":"J Biol Chem"},{"key":"329_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bcp.2012.10.012","volume":"85","author":"G Benedetti","year":"2013","unstructured":"Benedetti G, Fredriksson L, Herpers B, Meerman J, van de Water B, de Graauw M. TNF-alpha-mediated NF-kappa B survival signaling impairment by cisplatiri enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem Pharmacol. 2013;85:274\u201386.","journal-title":"Biochem Pharmacol"},{"key":"329_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1124\/mol.112.084053","volume":"84","author":"G Benedetti","year":"2013","unstructured":"Benedetti G, Fokkelman M, Yan K, Fredriksson L, Herpers B, Meerman J, et al. The nuclear factor kappa B family member RelB facilitates apoptosis of renal epithelial cells caused by cisplatin\/tumor necrosis factor alpha synergy by suppressing an epithelial to mesenchymal transition-like phenotypic switchs. Mol Pharmacol. 2013;84:128\u201338.","journal-title":"Mol Pharmacol"},{"key":"329_CR36","first-page":"5396","volume":"58","author":"N Keshelava","year":"1998","unstructured":"Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58:5396\u2013405.","journal-title":"Cancer Res"},{"key":"329_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/0-306-46872-7_2","volume-title":"Human cell culture","author":"CJ Thiele","year":"1998","unstructured":"Thiele CJ. Neuroblastoma. In: Lancaster MJ, editor. Human cell culture, vol. 1. UK: Kluwer Academic Publishers; 1998. p. 21\u201353."},{"key":"329_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.bbrc.2007.01.057","volume":"354","author":"Y Nakamura","year":"2007","unstructured":"Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun. 2007;354:892\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"329_CR39","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1016\/S0002-9440(10)64678-0","volume":"158","author":"DA Tweddle","year":"2001","unstructured":"Tweddle DA, Malcolm AJ, Cole M, Pearson ADJ, Lunec J. p53 Cellular localization and function in neuroblastoma - evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol. 2001;158:2067\u201377.","journal-title":"Am J Pathol"},{"key":"329_CR40","first-page":"6185","volume":"61","author":"N Keshelava","year":"2001","unstructured":"Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines'. Cancer Res. 2001;61:6185\u201393.","journal-title":"Cancer Res"},{"key":"329_CR41","first-page":"127","volume":"7","author":"AM Davidoff","year":"1992","unstructured":"Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of P53 in human neuroblastoma-derived and neuroepithelioma-derived cell-lines. Oncogene. 1992;7:127\u201333.","journal-title":"Oncogene"},{"key":"329_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ni.2065","volume":"12","author":"A Oeckinghaus","year":"2011","unstructured":"Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappa B signaling pathways. Nat Immunol. 2011;12:695\u2013708.","journal-title":"Nat Immunol"},{"key":"329_CR43","doi-asserted-by":"crossref","unstructured":"Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biol. 2012;13:R95.","DOI":"10.1186\/gb-2012-13-10-r95"},{"key":"329_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.cdd.4401132","volume":"10","author":"I Petak","year":"2003","unstructured":"Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ. 2003;10:211\u20137.","journal-title":"Cell Death Differ"},{"key":"329_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mc.1062","volume":"32","author":"S Santourlidis","year":"2001","unstructured":"Santourlidis S, Warskulat U, Florl AR, Maas S, Pulte T, Fischer J, et al. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95\/Apo-1) gene promoter at rel\/nuclear factor kappa B sites in prostatic carcinoma. Mol Carcinog. 2001;32:36\u201343.","journal-title":"Mol Carcinog"},{"key":"329_CR46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jpedsurg.2003.12.009","volume":"39","author":"S Kim","year":"2004","unstructured":"Kim S, Kang JH, Evers BM, Chung DH. Interferon-gamma induces caspase-8 in neuroblastomas without affecting methylation of caspase-8 promoter. J Pediatr Surg. 2004;39:509\u201315.","journal-title":"J Pediatr Surg"},{"key":"329_CR47","first-page":"157","volume":"1028","author":"I Casciano","year":"2004","unstructured":"Casciano I, Banelli B, Croce M, De Ambrosis A, Di Vinci A, Gelvi I, et al. Caspase-8 gene expression in neuroblastoma. Signal Transduct Commun Cancer Cells. 2004;1028:157\u201367.","journal-title":"Signal Transduct Commun Cancer Cells"},{"key":"329_CR48","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/bjc.2013.421","volume":"109","author":"T Hemmerle","year":"2013","unstructured":"Hemmerle T, Probst P, Giovannoni L, Green AJ, Meyer T, Neri D. The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer. 2013;109:1206\u201313.","journal-title":"Br J Cancer"},{"key":"329_CR49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/jso.23168","volume":"107","author":"F Papadia","year":"2013","unstructured":"Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol. 2013;107:173\u20139.","journal-title":"J Surg Oncol"},{"key":"329_CR50","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/biof.50","volume":"35","author":"J Gerspach","year":"2009","unstructured":"Gerspach J, Pfizenmaier K, Wajant H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors. 2009;35:364\u201372.","journal-title":"Biofactors"},{"key":"329_CR51","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00432-012-1327-7","volume":"139","author":"G Spitaleri","year":"2013","unstructured":"Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, et al. Phase I\/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol. 2013;139:447\u201355.","journal-title":"J Cancer Res Clin Oncol"},{"key":"329_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2012.44.8589","volume":"31","author":"S Ferrari","year":"2013","unstructured":"Ferrari S, Casali PG, Blay JY, Tonini G, Le Cesne A, Ali N, et al. Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). J Clin Oncol. 2013;31:1.","journal-title":"J Clin Oncol"},{"key":"329_CR53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","volume":"12","author":"ND Perkins","year":"2012","unstructured":"Perkins ND. The diverse and complex roles of NF-kappa B subunits in cancer. Nat Rev Cancer. 2012;12:121\u201332.","journal-title":"Nat Rev Cancer"},{"key":"329_CR54","doi-asserted-by":"crossref","unstructured":"Hoesel B, Schmid JA. The complexity of NF-kappa B signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","DOI":"10.1186\/1476-4598-12-86"},{"key":"329_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1471-4159.2002.00880.x","volume":"81","author":"Y Shou","year":"2002","unstructured":"Shou Y, Li NY, Li L, Borowitz JL, Isom GE. NF-kappa B-mediated up-regulation of Bcl-X-S and Bax contributes to cytochrome c release in cyanide-induced apoptosis. J Neurochem. 2002;81:842\u201352.","journal-title":"J Neurochem"},{"key":"329_CR56","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1128\/MCB.25.13.5404-5416.2005","volume":"25","author":"S Shetty","year":"2005","unstructured":"Shetty S, Graham BA, Brown JG, Hu XJ, Vegh-Yarema N, Harding G, et al. Transcription factor NF-kappa B differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005;25:5404\u201316.","journal-title":"Mol Cell Biol"},{"key":"329_CR57","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1038\/sj.onc.1204985","volume":"20","author":"GM Kasof","year":"2001","unstructured":"Kasof GM, Lu JJ, Liu DR, Speer B, Mongan KN, Gomes BC, et al. Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappa B. Oncogene. 2001;20:7965\u201375.","journal-title":"Oncogene"},{"key":"329_CR58","doi-asserted-by":"publisher","first-page":"22323","DOI":"10.1074\/jbc.M100072200","volume":"276","author":"VJ Yuste","year":"2001","unstructured":"Yuste VJ, Bayascas JR, Llecha N, Sanchez-Lopez I, Boix J, Comella JX. The absence of oligonucleosomal DNA fragmentation during apoptosis of IMR-5 neuroblastoma cells - disappearance of the caspase-activated DNase. J Biol Chem. 2001;276:22323\u201331.","journal-title":"J Biol Chem"},{"key":"329_CR59","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1083\/jcb.200403093","volume":"167","author":"C Sole","year":"2004","unstructured":"Sole C, Dolcet X, Segura MF, Gutierrez H, Diaz-Meco MT, Gozzelino R, et al. The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-kappa B signaling. J Cell Biol. 2004;167:479\u201392.","journal-title":"J Cell Biol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-015-0329-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0329-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T09:45:42Z","timestamp":1630575942000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-015-0329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,19]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1186\/s12943-015-0329-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,19]]},"assertion":[{"value":"7 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"62"}}